S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
Why Your IRA Could Crash on June 16th (Ad)
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
Why Your IRA Could Crash on June 16th (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
Why Your IRA Could Crash on June 16th (Ad)
Teen workers are in high demand for summer and commanding better pay
Biden, GOP reach tentative deal to raise debt ceiling, avoid calamitous US default
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
Why Your IRA Could Crash on June 16th (Ad)
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
Why Your IRA Could Crash on June 16th (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
Why Your IRA Could Crash on June 16th (Ad)
Teen workers are in high demand for summer and commanding better pay
Biden, GOP reach tentative deal to raise debt ceiling, avoid calamitous US default
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
Why Your IRA Could Crash on June 16th (Ad)
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
Why Your IRA Could Crash on June 16th (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
Why Your IRA Could Crash on June 16th (Ad)
Teen workers are in high demand for summer and commanding better pay
Biden, GOP reach tentative deal to raise debt ceiling, avoid calamitous US default
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
Why Your IRA Could Crash on June 16th (Ad)
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
Why Your IRA Could Crash on June 16th (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
Why Your IRA Could Crash on June 16th (Ad)
Teen workers are in high demand for summer and commanding better pay
Biden, GOP reach tentative deal to raise debt ceiling, avoid calamitous US default
NASDAQ:COCP

Cocrystal Pharma (COCP) Stock Forecast, Price & News

$2.26
+0.03 (+1.35%)
(As of 05/26/2023 ET)
Compare
Today's Range
$2.20
$2.38
50-Day Range
$1.80
$2.81
52-Week Range
$1.74
$6.24
Volume
41,836 shs
Average Volume
33,559 shs
Market Capitalization
$22.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.00

Cocrystal Pharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
431.0% Upside
$12.00 Price Target
Short Interest
Healthy
0.54% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.01mentions of Cocrystal Pharma in the last 14 days
Based on 9 Articles This Week
Insider Trading
Acquiring Shares
$2 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.13) to ($1.65) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.43 out of 5 stars

Medical Sector

645th out of 1,018 stocks

Pharmaceutical Preparations Industry

323rd out of 498 stocks


COCP stock logo

About Cocrystal Pharma (NASDAQ:COCP) Stock

Cocrystal Pharma, Inc. is a biotechnology company, which engages in the discovery and development of novel antiviral therapeutics. It focuses on the preclinical and early clinical stage antiviral compounds for unmet medical needs including influenza, Hepatitis C virus, and norovirus infections. The company was founded in 2008 and is headquartered in Bothell, WA.

Receive COCP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cocrystal Pharma and its competitors with MarketBeat's FREE daily newsletter.

COCP Stock News Headlines

15 A.I. Trading Opportunities a Day
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
H.C. Wainwright Keeps Their Buy Rating on Cocrystal Pharma (COCP)
3 Free Stock Picks per Day
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
COCP Cocrystal Pharma, Inc.
See More Headlines
Receive COCP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cocrystal Pharma and its competitors with MarketBeat's FREE daily newsletter.

COCP Company Calendar

Last Earnings
3/29/2023
Today
5/27/2023
Next Earnings (Estimated)
8/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:COCP
Fax
N/A
Employees
13
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$12.00
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+431.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-38,840,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$2.01 million
Cash Flow
$0.17 per share
Book Value
$3.41 per share

Miscellaneous

Free Float
9,614,000
Market Cap
$22.98 million
Optionable
Not Optionable
Beta
1.19

Key Executives

  • Sam Lee
    President & Co-Chief Executive Officer
  • James Joseph Martin
    Co-Chief Executive Officer, CFO & Secretary
  • Luz Pascual
    Vice President-Clinical Development













COCP Stock - Frequently Asked Questions

Should I buy or sell Cocrystal Pharma stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cocrystal Pharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" COCP shares.
View COCP analyst ratings
or view top-rated stocks.

What is Cocrystal Pharma's stock price forecast for 2023?

1 analysts have issued twelve-month price targets for Cocrystal Pharma's shares. Their COCP share price forecasts range from $12.00 to $12.00. On average, they expect the company's stock price to reach $12.00 in the next year. This suggests a possible upside of 431.0% from the stock's current price.
View analysts price targets for COCP
or view top-rated stocks among Wall Street analysts.

How have COCP shares performed in 2023?

Cocrystal Pharma's stock was trading at $1.95 at the start of the year. Since then, COCP stock has increased by 15.9% and is now trading at $2.26.
View the best growth stocks for 2023 here
.

Are investors shorting Cocrystal Pharma?

Cocrystal Pharma saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 34,100 shares, a decrease of 13.7% from the April 30th total of 39,500 shares. Based on an average daily trading volume, of 70,200 shares, the days-to-cover ratio is presently 0.5 days. Approximately 0.5% of the shares of the company are short sold.
View Cocrystal Pharma's Short Interest
.

When is Cocrystal Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our COCP earnings forecast
.

How were Cocrystal Pharma's earnings last quarter?

Cocrystal Pharma, Inc. (NASDAQ:COCP) posted its quarterly earnings results on Wednesday, March, 29th. The company reported ($0.55) earnings per share for the quarter, beating analysts' consensus estimates of ($0.72) by $0.17.

When did Cocrystal Pharma's stock split?

Shares of Cocrystal Pharma reverse split before market open on Tuesday, October 11th 2022. The 1-12 reverse split was announced on Tuesday, October 11th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 11th 2022. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What other stocks do shareholders of Cocrystal Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cocrystal Pharma investors own include Moderna (MRNA), Hello Group (MOMO), Intra-Cellular Therapies (ITCI), Impala Platinum (IMPUY), GenMark Diagnostics (GNMK), Gevo (GEVO), Auxly Cannabis Group (CBWTF), Bionano Genomics (BNGO), Blink Charging (BLNK) and Bilibili (BILI).

What is Cocrystal Pharma's stock symbol?

Cocrystal Pharma trades on the NASDAQ under the ticker symbol "COCP."

Who are Cocrystal Pharma's major shareholders?

Cocrystal Pharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (1.18%), Sabby Management LLC (0.65%) and Susquehanna International Group LLP (0.20%). Insiders that own company stock include Phillip Md Et Al Frost, Raymond F Schinazi and Richard C Pfenniger, Jr.
View institutional ownership trends
.

How do I buy shares of Cocrystal Pharma?

Shares of COCP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cocrystal Pharma's stock price today?

One share of COCP stock can currently be purchased for approximately $2.26.

How much money does Cocrystal Pharma make?

Cocrystal Pharma (NASDAQ:COCP) has a market capitalization of $22.98 million and generates $2.01 million in revenue each year. The company earns $-38,840,000.00 in net income (profit) each year or ($4.8912) on an earnings per share basis.

How can I contact Cocrystal Pharma?

Cocrystal Pharma's mailing address is 19805 N. CREEK PARKWAY, BOTHELL WA, 98011. The official website for the company is www.cocrystalpharma.com. The company can be reached via phone at (305) 425-1780 or via email at cocp@jtcir.com.

This page (NASDAQ:COCP) was last updated on 5/27/2023 by MarketBeat.com Staff

My Account -